96
Participants
Start Date
January 10, 2020
Primary Completion Date
February 28, 2023
Study Completion Date
February 28, 2023
CK-3773274 (5 - 15 mg)
CK-3773274 tablets administered orally
CK-3773274 (10 - 30 mg)
CK-3773274 tablets administered orally
Placebo for CK-3773274
Placebo administered orally
New York University Langone Health Medical Center, New York
Complejo Hospitalario Universitario A Coruña, A Coruña
UMPC Heart and Vascular Institute, Pittsburgh
Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine), Philadelphia
University of Virginia Health System, Charlottesville
Duke Cardiology at Southpoint, Durham
Carolinas Medical Center, Charlotte
Michigan Medicine - University of Michigan, Ann Arbor
Northwestern University, Evanston
Washington University School of Medicine, St Louis
UT Southwestern Medical Center, Dallas
Houston Methodist Hospital, Houston
Intermountain Medical Center, Murray
Cedar-Sinai Medical Center, Los Angeles
UCSF Medical Center, San Francisco
Oregon Health and Science University, Portland
Tufts Medical Center, Boston
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Azienda Ospedaliero Universitaria Careggi, Florence
Erasmus University Medical Center (Erasmus MC), Rotterdam
Hospital Universitario Puerta de Hierro de Majadahonda, Madrid
Lead Sponsor
Cytokinetics
INDUSTRY